Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy
JAMA Internal Medicine · 01.09.2023 · 183 (9) · 944
DOI: 10.1001/jamainternmed.2023.2986 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Internal Medicine, erschienen am 01.09.2023. Verfasst von Ana Maria Copaescu und 24 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia. Hauptthemen laut MEDLINE: Drug Hypersensitivity, Hypersensitivity. Die Arbeit wurde bisher 217-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Fewer than 5% of patients labeled with a penicillin allergy are truly allergic. The standard of care to remove the penicillin allergy label in adults is specialized testing involving prick and intradermal skin testing followed by an oral challenge with penicillin. Skin testing is resource intensive, limits practice to specialist-trained physicians, and restricts the global population who could undergo penicillin allergy delabeling.
Objective
To determine whether a direct oral penicillin challenge is noninferior to the standard of care of penicillin skin testing followed by an oral challenge in patients with a low-risk penicillin allergy. Design, Setting, and Participants This parallel, 2-arm, noninferiority, open-label, multicenter, international randomized clinical trial occurred in 6 specialized centers, 3 in North America (US and Canada) and 3 in Australia, from June 18, 2021, to December 2, 2022. Eligible adults had a PEN-FAST score lower than 3. PEN-FAST is a prospectively derived and internationally validated clinical decision rule that enables point-of-care risk assessment for adults reporting penicillin allergies.
Interventions
Patients were randomly assigned to either direct oral challenge with penicillin (intervention arm) or a standard-of-care arm of penicillin skin testing followed by oral challenge with penicillin (control arm). Main Outcome and Measure The primary outcome was a physician-verified positive immune-mediated oral penicillin challenge within 1 hour postintervention in the intention-to-treat population. Noninferiority was achieved if a 1-sided 95% CI of the risk difference (RD) did not exceed 5 percentage points (pp).
Results
A total of 382 adults were randomized, with 377 patients (median [IQR] age, 51 [35-65] years; 247 [65.5%] female) included in the analysis: 187 in the intervention group and 190 in the control group. Most patients had a PEN-FAST score of 0 or 1. The primary outcome occurred in 1 patient (0.5%) in the intervention group and 1 patient (0.5%) in the control group, with an RD of 0.0084 pp (90% CI, −1.22 to 1.24 pp). The 1-sided 95% CI was below the noninferiority margin of 5 pp. In the 5 days following the oral penicillin challenge, 9 immune-mediated adverse events were recorded in the intervention group and 10 in the control group (RD, −0.45 pp; 95% CI, −4.87 to 3.96 pp). No serious adverse events occurred. Conclusions and Relevance In this randomized clinical trial, direct oral penicillin challenge in patients with a low-risk penicillin allergy was noninferior compared with standard-of-care skin testing followed by oral challenge. In patients with a low-risk history, direct oral penicillin challenge is a safe procedure to facilitate the removal of a penicillin allergy label. Trial Registration ClinicalTrials.gov Identifier: NCT04454229
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia.
- Division of Allergy and Clinical Immunology, Department of Medicine, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
- The Research Institute of the McGill University Health Centre, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
- Department of Medicine, Austin Health, The University of Melbourne, Melbourne, Victoria, Australia.
- Department of Medicine, St Vincent's Hospital, The University of Melbourne, Melbourne, Victoria, Australia.
- The National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Zitieren
APA
Copaescu, A. M., Vogrin, S., James, F., Chua, K. Y. L., Rose, M. T., De Luca, J., Waldron, J., Awad, A., Godsell, J., Mitri, E., Lambros, B., Douglas, A., Youcef Khoudja, R., Isabwe, G. A. C., Genest, G., Fein, M., Radojicic, C., Collier, A., Lugar, P., …, & Trubiano, J. A. (2023). Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy. JAMA Internal Medicine, 183(9), 944. https://doi.org/10.1001/jamainternmed.2023.2986
Vancouver
Copaescu AM, Vogrin S, James F, Chua KYL, Rose MT, De Luca J, et al. Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy. JAMA Internal Medicine. 2023;183(9):944. doi:10.1001/jamainternmed.2023.2986
BibTeX
@article{Copaescu2023,
author = {Copaescu, Ana Maria and Vogrin, Sara and James, Fiona and Chua, Kyra Y L and Rose, Morgan T and De Luca, Joseph and Waldron, Jamie and Awad, Andrew and Godsell, Jack and Mitri, Elise and Lambros, Belinda and Douglas, Abby and Youcef Khoudja, Rabea and Isabwe, Ghislaine A C and Genest, Genevieve and Fein, Michael and Radojicic, Cristine and Collier, Ann and Lugar, Patricia and Stone, Cosby and Ben-Shoshan, Moshe and Turner, Nicholas A and Holmes, Natasha E and Phillips, Elizabeth J and Trubiano, Jason A},
title = {Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy},
journal = {JAMA Internal Medicine},
year = {2023},
volume = {183},
number = {9},
pages = {944},
doi = {10.1001/jamainternmed.2023.2986}
}
EUVIMED